New York City, NY (PRWEB) January 24, 2013
CBPartners, one of the world’s leading authorities on issues related to the demonstration of value in support of pricing and market access strategy within the biopharmaceutical industry, officially publishes the analysis this afternoon at 1500 EST / 2100 CET. The piece, entitled “Guardians of Opportunity: Emerging HTA in Brazil, South Korea, and Taiwan” was collaboratively developed by Dr. Beckerman, Principal in the Value Demonstration practice in the New York City office, and Shinkyu Park, Analyst in the New York City office.
HTA, or Health Technology Assessment, is an evidence-based policy intervention applied by payers of biopharmaceuticals and other healthcare interventions. It is believed that HTA can lead to optimised expenditure of healthcare resources – however the most effective methodology of HTA is still contested among healthcare policy authorities around the world. During the past 15 years, HTA has flourished in Western European countries like England, Sweden, Scotland, Germany, and France. HTA has also been established in Commonwealth countries like Canada and Australia.
Until recently, however, HTA was not fully or consistently implemented in the emerging economies – and many argue that it is still not effectively employed in these markets. “Most biopharmaceutical manufacturers believe that the emerging economies represent great opportunity due to the rapidly evolving ability and willingness to pay for the latest in healthcare innovation,” explains Dr. Beckerman. “The use of HTA as a tool to efficiently spend financial resources on healthcare innovations is just now reaching countries like Brazil, Korea, and Taiwan. Thus far, we have learned of several telling case studies which indicate the additional degree of difficulty experienced by biopharmaceutical innovators through these policies.”
Many claim that emerging markets are not ready for the complicated methods and ramifications of an HTA-based system for determining access to innovative medicines. “No payer of biopharmaceuticals – anywhere in the world – has determined the perfect solution for evaluating value-for-money,” states Cyrus A. Chowdhury, Chief Executive Officer of CBPartners. “With cost-effectiveness methods ranging broadly from cost-utility to cost-minimisation and non-monetised incremental benefit assessments, it is clear that there is no consensus solution that can be applied to each society. This diversity of methods carries significant risk to biopharmaceutical manufacturers attempting to develop a concise global evidence strategy – risk that significantly increases through the addition of HTA to the already complex emerging market environment.”
Distribution of the thought piece is currently limited to clients of CBPartners, however the piece will be more broadly available in 90 days. For more information, please visit http://www.cbpartners.com.
CBPartners is a leading global strategy consulting firm focusing on healthcare issues for a variety of clients, including biopharmaceutical companies, medical device companies and government health authorities. Headquartered in New York City, CBPartners maintains a continuous throughput of local market intelligence updates from advisors throughout 73 markets. CBPartners provides expertise through five practice areas including Pricing and Market Access, Value Demonstration, Portfolio Optimisation, Commercial Planning, and Government Policy Advisory.
To find out more, please contact Cyrus Chowdhury, Managing Director of the New York City office at cyrus(dot)chowdhury(at)c-b-partners(dot)com, visit http://www.c-b-partners.com, or follow CBPartners on Twitter: http://www.twitter.com/CBPartners.